RBC Capital analyst Brian Abrahams maintained a Hold rating on Biogen Inc (NASDAQ:BIIB) on Tuesday, setting a price target of $303, which is approximately 0.05% above the present share price of $302.86.
Abrahams expects Biogen Inc to post earnings per share (EPS) of $8.10 for the second quarter of 2020.
The current consensus among 20 TipRanks analysts is for a Hold rating of shares in Biogen, with an average price target of $320.24.
The analysts price targets range from a high of $392 to a low of $240.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $3.53 billion and a net profit of $1.89 billion. The company's market cap is $49.38 billion.
According to TipRanks.com, RBC Capital analyst Brian Abrahams is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 12.6% and a 55.16% success rate.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp (OTC:SHCAY) in 1978 and is headquartered in Cambridge, MA.